Astellas’ drug fezolinetant (Veoza) has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the prevention of hot flashes during the menopause.
A treatment option to reduce the number and intensity of hot flashes and night sweats associated with menopause has been approved by the European Commission (EC).
US pharma firm Vivus is the happy recipient of a $140m milestone
payment following last month's decision by US regulators to approve
a novel spray-on estrogen treatment for menopausal women.
A new recombinant combo treatment that could help some of
the rising number of women experiencing fertility problems,
has now been approved for use in the Europe.
Neurocrine Biosciences has announced positive Phase I clinical
trial results with its proprietary, orally active small molecule
Gonadotropin-Releasing Hormone (GnRH) receptor antagonist that
could diminish bone demineralisation.
Dutch drug company, Organon, has initiated further studies to
develop a specific class of non-hormonal drugs to treat the hot
flushes associated with menopause. The new drug, currently in
development, is set to be amongst the first...
US drug giant Pfizer, has signed a license agreement to market a
specific class of non-hormonal drugs to treat the hot flushes
associated with menopause. The new drug,currently in development,
is set to become the first of its kind...